fls.txt



item1.txt
The accompanying unaudited interim condensed consolidated financial statements are prepared pursuant to the Securities and Exchange Commission’s rules and regulations for reporting on Form 10-Q.
The Company believes all adjustments necessary for a fair presentation of these interim statements have been included and that they are of a normal and recurring nature.
All material intercompany balances and transactions have been eliminated.
Refer to Note 8, "Leases", for related disclosures.
The Company records revenues in accordance with Accounting Standards Codification (“ASC”) Topic 606 “Revenue from Contracts with Customers, as amended” (“ASC Topic 606”).
The following table summarizes the Company’s disaggregation of revenues for the three months ended September 30, 2019 and 2018.
Customers either pay by credit card (online sales) or net 30-90, depending on the customer.
The standard warranty is typically comprised of one to two years of parts and labor and is deemed immaterial.
Some contracts call for training and installation, which is considered ancillary and not a material part of the contract.
Catalyst research instruments are never returned for repairs.
Approximately 33% and 25% of total Benchtop Laboratory Equipment sales were derived from the Torbal Scales Division for the three months ended September 30, 2019 and 2018, respectively.
For the three months ended September 30, 2019 and 2018, respectively, three customers accounted for approximately 23% (both periods) of net sales of the Benchtop Laboratory Equipment Operations (18% and 19% of the Company’s total revenues).
The FASB defines the fair value of financial instruments as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.
Fair value measurements do not include transaction costs.
Level 1 - Inputs that are based upon unadjusted quoted prices for identical instruments traded in active markets.
Level 2 - Quoted prices in markets that are not considered to be active or financial instruments for which all significant inputs are observable, either directly or indirectly.
The fair value of the contingent consideration obligations are based on a probability weighted approach derived from the estimates of earn-out criteria and the probability assessment with respect to the likelihood of achieving those criteria.


item2.txt
Item 2.
Forward-Looking statements.
Consequently, no forward-looking statement can be guaranteed.
Overview.
Sales of Catalyst Research Instruments decreased by $78,800 to $138,700 for the three months ended September 30, 2019 compared to $217,500 for the three months ended September 30, 2018 due to low order input during the period.
The gross profit percentage on a combined basis was 48.9% for the three months ended September 30, 2019 compared to 46.4% for the three months ended September 30, 2018.
As a result of the foregoing, the Company recorded a net loss of $56,200 for the three months ended September 30, 2019 compared to net income of $142,000 for the three months ended September 30, 2018.
Net cash used in operating activities was $324,100 for the three months ended September 30, 2019 compared to net cash provided by operating activities of $460,700 during the three months ended September 30, 2018, primarily as a result of the loss incurred for the current year period.
The Company received proceeds of $7,000 in financing activities in the three months ended September 30, 2019 compared to a loss of $1,600 in the three months ended September 30, 2018 due to the exercise of stock options in the current year.


